

Piera Capranzano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1645741/publications.pdf>

Version: 2024-02-01

184
papers

6,209
citations

70961

41
h-index

79541

73
g-index

213
all docs

213
docs citations

213
times ranked

6546
citing authors

#	ARTICLE	IF	CITATIONS
1	European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. <i>European Heart Journal</i> , 2018, 39, 3353-3368.	1.0	421
2	Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. <i>EuroIntervention</i> , 2015, 10, 1144-1153.	1.4	411
3	Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography-Guided Percutaneous Coronary Intervention With Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2488-2498.	1.1	209
4	A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. <i>European Heart Journal</i> , 2008, 29, 2202-2211.	1.0	183
5	Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 180-187.	1.4	172
6	Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	164
7	Usefulness of SYNTAX Score to Select Patients With Left Main Coronary Artery Disease to Be Treated With Coronary Artery Bypass Graft. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 731-738.	1.1	150
8	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. <i>EuroIntervention</i> , 2015, 11, 45-52.	1.4	131
9	A Simple Risk Tool (the OBSERVANT Score) for Prediction of 30-Day Mortality After Transcatheter Aortic Valve Replacement. <i>American Journal of Cardiology</i> , 2014, 113, 1851-1858.	0.7	126
10	Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1246-1255.	0.5	125
11	Drug-Eluting Stent for Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 718-727.	1.1	121
12	Global Risk Classification and Clinical SYNTAX (Synergy between Percutaneous Coronary Intervention) Tj ETQq0 0 0 rgBT /Overlock 10 T Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 287-297.	1.1	119
13	Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. <i>Circulation</i> , 2018, 137, 2435-2445.	1.6	116
14	Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. <i>EuroIntervention</i> , 2017, 12, 2110-2117.	1.4	114
15	EuroSCORE refines the predictive ability of SYNTAX score in patients undergoing left main percutaneous coronary intervention. <i>American Heart Journal</i> , 2010, 159, 103-109.	1.2	108
16	Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1595-1604.	1.1	108
17	Extended Use of Percutaneous Edge-to-Edge Mitral Valve Repair Beyond EVEREST (Endovascular Valve) Tj ETQq1 1,0,784314 rgBT /Oe	1.1	108
18	Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. <i>BMJ, The</i> , 2015, 351, h5392.	3.0	102

#	ARTICLE	IF	CITATIONS
19	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. <i>Annals of Internal Medicine</i> , 2016, 165, 334.	2.0	102
20	Pharmacology of emerging novel platelet inhibitors. <i>American Heart Journal</i> , 2008, 156, 10S-15S.	1.2	97
21	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1041-1057.	1.2	92
22	Acute and 30-Day Outcomes in Women After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1589-1600.	1.1	85
23	Early discharge after transfemoral transcatheter aortic valve implantation. <i>Heart</i> , 2015, 101, 1485-1490.	1.2	80
24	Incidence of Long-Term Structural Valve Dysfunction and Bioprosthetic Valve Failure After Transcatheter Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2018, 7, e008440.	1.6	80
25	Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients. <i>International Journal of Cardiology</i> , 2013, 167, 1237-1241.	0.8	79
26	1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1-12.	1.1	77
27	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected Left Main Coronary Artery. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1242-1249.	1.1	75
28	Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A meta-analysis of 5,971 patients. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 518-527.	0.7	75
29	Moderate and Severe Preoperative Chronic Kidney Disease Worsen Clinical Outcomes After Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002220.	1.4	73
30	Current status of transcatheter valve therapy in Europe: results from an EAPCI survey. <i>EuroIntervention</i> , 2016, 12, 890-895.	1.4	70
31	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis. <i>International Journal of Cardiology</i> , 2017, 231, 162-169.	0.8	69
32	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 253-262.	0.4	66
33	Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 30-39.	1.2	58
34	Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 448-456.	0.7	57
35	Cigarette Smoking Is Associated With a Dose-Response Effect in Clopidogrel-Treated Patients With Diabetes Mellitus and Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 293-300.	1.1	48
36	Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2015, 11, 690-697.	1.4	48

#	ARTICLE	IF	CITATIONS
37	Motivations for and barriers to choosing an interventional cardiology career path: results from the EAPCI Women Committee worldwide survey. <i>EuroIntervention</i> , 2016, 12, 53-59.	1.4	48
38	Left Cardiac Chambers Reverse Remodeling after Percutaneous Mitral Valve Repair with the MitraClip System. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 1099-1105.	1.2	45
39	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 354-361.	1.1	45
40	Meta-Analysis of Randomized Controlled Trials of Preprocedural Statin Administration for Reducing Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Catheterization. <i>American Journal of Cardiology</i> , 2014, 114, 541-548.	0.7	44
41	Gender-related clinical and echocardiographic outcomes at 30-day and 12-month follow up after MitraClip implantation in the GRASP registry. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 889-897.	0.7	44
42	Prasugrel: a novel platelet ADP P2Y ₁₂ receptor antagonist. A review on its mechanism of action and clinical development. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2893-2900.	0.9	43
43	Comparison of One-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Unprotected Left Main Coronary Artery Disease and Acute Coronary Syndromes (from the CUSTOMIZE Registry). <i>American Journal of Cardiology</i> , 2011, 108, 355-359.	0.7	39
44	Impact of P2Y ₁₂ Inhibitory Effects Induced by Clopidogrel on Platelet Procoagulant Activity in Type 2 Diabetes Mellitus Patients. <i>Thrombosis Research</i> , 2009, 124, 318-322.	0.8	37
45	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. <i>Thrombosis and Haemostasis</i> , 2011, 106, 253-262.	1.8	37
46	Pharmacokinetics of new oral anticoagulants: implications for use in routine care. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1057-1069.	1.5	37
47	Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 1-14.	0.7	36
48	Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. <i>Thrombosis and Haemostasis</i> , 2011, 106, 67-74.	1.8	36
49	Functional profile of the platelet P2Y ₁₂ receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2011, 105, 730-732.	1.8	34
50	Plaque Distribution Patterns in Distal Left Main Coronary Artery to Predict Outcomes After Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 624-631.	1.1	33
51	Percutaneous Mitral Valve Repair With the MitraClip System for Severe Mitral Regurgitation in Patients With Surgical Mitral Valve Repair Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 836-838.	1.2	33
52	Objectifying the impact of incomplete revascularization by repeat angiographic risk assessment with the residual SYNTAX score after left main coronary artery percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 333-340.	0.7	32
53	Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the GHOST registry. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 1150-1161.	0.7	32
54	Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1639-1640.	1.2	32

#	ARTICLE	IF	CITATIONS
55	Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. <i>EuroIntervention</i> , 2016, 12, e550-e556.	1.4	32
56	A Risk Model for Prediction of 1-Year Mortality in Patients Undergoing MitraClip Implantation. <i>American Journal of Cardiology</i> , 2017, 119, 1443-1449.	0.7	31
57	Percutaneous recanalization of chronic total occlusions: Wherein lies the body of proof?. <i>American Heart Journal</i> , 2013, 165, 133-142.	1.2	30
58	Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1149-1157.	1.8	29
59	Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 47-56.	0.7	28
60	Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians (from a Drug-Eluting stent for Left main) <i>TJ ETQq0 0 0 rgBT0,0verlock210 Tf 50 5</i>		
61	Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2280-2288.	1.1	26
62	Validating the EXCEL hypothesis: A propensity score matched 3-year comparison of percutaneous coronary intervention versus coronary artery bypass graft in left main patients with SYNTAX score ≥ 32 . <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 936-943.	0.7	25
63	Optimized Screening of Coronary Artery Disease With Invasive Coronary Angiography and Ad Hoc Percutaneous Coronary Intervention During Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	25
64	Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 155-164.	1.0	24
65	New-onset atrial fibrillation and increased mortality after transcatheter aortic valve implantation: A causal or spurious association?. <i>International Journal of Cardiology</i> , 2016, 203, 264-266.	0.8	24
66	Impact of chronic kidney disease on outcomes after percutaneous mitral valve repair with the MitraClip system: insights from the GRASP registry. <i>EuroIntervention</i> , 2016, 11, e1649-e1657.	1.4	24
67	Real world safety and efficacy of the Janus tacrolimus-eluting stent: Long-term clinical outcome and angiographic findings from the tacrolimus-eluting stent (TEST) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 243-248.	0.7	23
68	Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1185-1203.	0.6	23
69	Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. <i>American Heart Journal</i> , 2016, 176, 44-52.	1.2	23
70	1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 440-449.	1.1	23
71	Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 291-298.	0.7	22
72	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1124-1131.	0.7	22

#	ARTICLE	IF	CITATIONS
73	Antithrombotic Management of Elderly Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 723-738.	1.1	22
74	Long-term outcomes after drug-eluting stent for the treatment of ostial left anterior descending coronary artery lesions. <i>American Heart Journal</i> , 2010, 160, 973-978.	1.2	19
75	Percutaneous mitral valve repair with the MitraClip system in the elderly: One-year outcomes from the GRASP registry. <i>International Journal of Cardiology</i> , 2016, 224, 440-446.	0.8	19
76	Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on-treatment platelet reactivity and diabetes mellitus status. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 42-49.	0.7	18
77	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1909-1916.	0.7	18
78	Personalizing oral anticoagulant treatment in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 959-973.	0.6	17
79	Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing <sc>TAVI</sc> for severe aortic stenosis: Insights from the <sc>WIN-TAVI</sc> registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 516-526.	0.7	17
80	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. <i>EuroIntervention</i> , 2016, 12, e623-e631.	1.4	17
81	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 560-568.	1.1	16
82	Late Stent Thrombosis: The Last Remaining Obstacle in Coronary Interventional Therapy. <i>Current Cardiology Reports</i> , 2012, 14, 408-417.	1.3	15
83	Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2016, 375, 699-701.	13.9	15
84	Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 475-486.	0.4	15
85	Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 812-818.	0.7	15
86	Incidence, Timing, Causes and Predictors of Early and Late Re-Hospitalization in Patients Who Underwent Percutaneous Mitral Valve Repair With the MitraClip System. <i>American Journal of Cardiology</i> , 2018, 121, 1253-1259.	0.7	15
87	Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the Tj ETQq1 1 0,784314 rgBT /Ove... <i>Cardiology</i> , 2014, 113, 1348-1355.	0.7	14
88	Early cardiovascular remodelling in Fabry disease. <i>Journal of Inherited Metabolic Disease</i> , 2014, 37, 109-116.	1.7	14
89	Tailoring P2Y ₁₂ Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2019, 8, e014000.	1.6	13
90	The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's International Transcatheter Aortic Valve Implantation (WIN-TAVI) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 198-207.	0.7	13

#	ARTICLE	IF	CITATIONS
91	Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee. <i>EuroIntervention</i> , 2018, 14, e1227-e1235.	1.4	13
92	A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score. <i>Clinical Research in Cardiology</i> , 2009, 98, 240-248.	1.5	12
93	Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 361-369.	0.6	12
94	Comparative One-Year Effectiveness of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients <75 Versus >75 Years With Unprotected Left Main Disease (from the Tj ETQq0 007gBT /Overlock 10		
95	Acute Left Atrial Spontaneous Echocardiographic Contrast and Suspicious Thrombus Formation Following Mitral Regurgitation Reduction With the MitraClip System. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1322-1323.	1.1	11
96	Everolimusâ€eluting bioresorbable vascular scaffolds versus second generation drugâ€eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the G<scp>HOSTâ€CTO</scp> registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E155-E163.	0.7	11
97	Procedural Management of Patients With Advanced Heart Failure Undergoing MitraClip Implantation (From the GRASP Registry). <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, e6-e8.	0.6	11
98	Decision Analytic Markov Model Weighting Expected Benefits and Current Limitations of First-Generation Bioresorbable Vascular Scaffolds. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005768.	1.4	10
99	Current status of transcatheter mitral valve therapy in Europe: results from an EAPCI survey (Part II). <i>EuroIntervention</i> , 2017, 12, 1934-1939.	1.4	10
100	Predictors of long-term adverse events after Absorb bioresorbable vascular scaffold implantation: a 1,933-patient pooled analysis from international registries. <i>EuroIntervention</i> , 2019, 15, 623-630.	1.4	10
101	Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 411-422.	0.6	9
102	Impacto del tratamiento adyuvante con cilostazol comparado con dosis altas de mantenimiento de clopidogrel en pacientes con diabetes mellitus y respuesta subÃ³ptima. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 105-106.	0.6	9
103	New insights on acute expansion and longitudinal elongation of bioresorbable vascular scaffolds in vivo and at bench test: A note of caution on reliance to compliance charts and nominal length. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, E99-E107.	0.7	9
104	Early results of MitraClip system implantation by real-time three-dimensional speckle-tracking left ventricle analysis. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 843-849.	0.6	9
105	Antithrombotic pharmacotherapy after transcatheter aortic valve implantation: an update. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 479-496.	0.6	9
106	Edwards SAPIEN Versus Medtronic Aortic Bioprosthesis in Women Undergoing Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2020, 125, 441-448.	0.7	9
107	Suitability for elderly with heart disease of a QR code-based feedback of drug intake: Overcoming limitations of current medication adherence telemonitoring systems.. <i>International Journal of Cardiology</i> , 2021, 327, 209-216.	0.8	9
108	Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry. <i>EuroIntervention</i> , 2017, 13, e1104-e1111.	1.4	9

#	ARTICLE	IF	CITATIONS
109	Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry. <i>EuroIntervention</i> , 2012, 7, 1062-1068.	1.4	9
110	Impact of diabetes mellitus on long-term follow-up of percutaneous coronary intervention based on clinical presentation of coronary artery disease. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 405-410.	0.6	8
111	Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the <sc>E</sc>uropean <sc>M</sc>ulticentre <sc>GHOST</sc> <sc>EU</sc> <sc>R</sc>egistry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 444-453.	0.7	8
112	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E704-E715.	0.7	8
113	Sirolimus versus paclitaxel-eluting stents in small coronary vessels: long-term outcomes from a single-center registry. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 365-368.	0.6	7
114	MitraClip Implantation for the Treatment of New-Onset Systolic Anterior Motion of the Mitral Valve After Transcatheter Aortic Valve Replacement. <i>Annals of Thoracic Surgery</i> , 2016, 102, e517-e519.	0.7	7
115	Feasibility and predictors of early discharge after percutaneous edge-to-edge mitral valve repair. <i>Heart</i> , 2017, 103, 931-936.	1.2	7
116	Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry. <i>International Journal of Cardiology</i> , 2018, 253, 45-49.	0.8	7
117	Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry. <i>Canadian Journal of Cardiology</i> , 2019, 35, 199-207.	0.8	7
118	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E908-E917.	0.7	7
119	One-year outcomes after Absorb bioresorbable vascular scaffold implantation in routine clinical practice. <i>EuroIntervention</i> , 2016, 12, e152-e159.	1.4	7
120	Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 161-168.	0.6	6
121	Percutaneous Mitral Valve Repair in Patients with Prior Cardiac Surgery. <i>Journal of Cardiac Surgery</i> , 2012, 27, 295-298.	0.3	6
122	Meta-analysis of everolimus-eluting stents versus first-generation drug-eluting stents in patients with left main coronary artery undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013, 168, 1718-1719.	0.8	6
123	Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 307-317.	0.6	6
124	Strategies and Outcomes of Repeat Mitral Valve Interventions after Failed MitraClip Therapy. <i>Cardiology</i> , 2017, 137, 114-120.	0.6	6
125	Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. <i>New England Journal of Medicine</i> , 2017, 377, 1790-1792.	13.9	6
126	Patients with non-ST segment elevation acute coronary syndromes managed without coronary revascularization: A population needing treatment improvement. <i>International Journal of Cardiology</i> , 2017, 245, 35-42.	0.8	6

#	ARTICLE	IF	CITATIONS
127	Early discharge in acute myocardial infarction after clinical and angiographic risk assessment. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 858-861.	0.6	5
128	Functional and clinical implications of cardiac resynchronization therapy on outcomes of diabetic patients with heart failure. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 396-400.	0.6	5
129	Increasing CHADS2 scores may attenuate the benefit of novel oral anticoagulants versus warfarin in reducing intracranial bleeding. <i>International Journal of Cardiology</i> , 2012, 161, 176-177.	0.8	5
130	CABG versus PCI in diabetic patients with multivessel disease after risk stratification by the SYNTAX score: A pooled analysis of the SYNTAX and FREEDOM trials. <i>International Journal of Cardiology</i> , 2014, 173, 548-549.	0.8	5
131	Impact of moderate preoperative chronic kidney disease on mortality after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2015, 189, 77-78.	0.8	5
132	Risk stratification after ST-segment elevation myocardial infarction. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1349-1360.	0.6	5
133	Usefulness of 3D OCT to Diagnose a Noncircumferential Open-Cell Stent Fracture. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 210-211.	2.3	5
134	Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 519-535.	0.6	5
135	Bioresorbable vascular scaffolds in left main coronary artery disease. <i>EuroIntervention</i> , 2015, 11, V135-V138.	1.4	5
136	Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. <i>Journal of the American Heart Association</i> , 2022, 11, e022320.	1.6	5
137	A post-hoc analysis of the CUSTOMIZE Registry on the differential impact of EuroSCORE and SYNTAX score in left main patients with intermediate Global Risk. <i>International Journal of Cardiology</i> , 2011, 150, 116-117.	0.8	4
138	Switching between P2Y12 inhibitors: Rationale, methods, and expected consequences. <i>Vascular Pharmacology</i> , 2019, 116, 4-7.	1.0	4
139	Ticagrelor or Clopidogrel in Elderly Patients With Myocardial Infarction. <i>Circulation</i> , 2020, 142, 1709-1712.	1.6	4
140	Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry). <i>American Journal of Cardiology</i> , 2022, 172, 73-80.	0.7	4
141	Clinical Impact of Enhanced Inhibition of P2Y ₁₂ -Mediated Platelet Aggregation in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>Hospital Practice (1995)</i> , 2010, 38, 38-43.	0.5	3
142	Initial experience of percutaneous coronary intervention in bifurcations with bioresorbable vascular scaffolds using different techniques – Insights from optical coherence tomography. <i>International Journal of Cardiology</i> , 2013, 170, e33-e35.	0.8	3
143	Longitudinal Elongation, Axial Compression, and Effects on Strut Geometry of Bioresorbable Vascular Scaffolds. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, e35-e37.	1.1	3
144	Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial. <i>International Journal of Cardiology</i> , 2015, 201, 276-278.	0.8	3

#	ARTICLE	IF	CITATIONS
145	Lipid Plaque Modification During Resorption of Absorb Bioresorbable Scaffold. JACC: Cardiovascular Interventions, 2018, 11, 2123-2124.	1.1	3
146	Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. International Journal of Cardiology, 2021, 322, 65-69.	0.8	3
147	Evidence and Recommendations for Uninterrupted Versus Interrupted Oral Anticoagulation in Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2021, 14, 764-767.	1.1	3
148	Clinical Development of Selective Anticoagulants: A State of the Art. Reviews on Recent Clinical Trials, 2010, 5, 85-93.	0.4	3
149	Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus. Revista Espanola De Cardiologia (English Ed), 2012, 65, 105-106.	0.4	2
150	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. European Heart Journal Supplements, 2014, 16, C2-C28.	0.0	2
151	TCT-419 Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds implantation: the PSP score. Journal of the American College of Cardiology, 2016, 68, B169-B170.	1.2	2
152	Management issues of chronic therapy with non-vitamin K oral anticoagulants or antiplatelet agents: Different or alike?. International Journal of Cardiology, 2016, 221, 695-696.	0.8	2
153	Embolization of Fractured Bioresorbable Scaffold Struts. JACC: Cardiovascular Interventions, 2016, 9, e37-e38.	1.1	2
154	Pharmacodynamics During Transition Between Platelet P2Y12 Inhibiting Therapies. Interventional Cardiology Clinics, 2019, 8, 321-340.	0.2	2
155	Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair. European Journal of Heart Failure, 2021, 23, 677-679.	2.9	2
156	Revascularization vs. Optimal Medical Therapy in Women with NSTEMI-ACS. Current Pharmaceutical Design, 2016, 22, 3905-3914.	0.9	2
157	Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry. EuroIntervention, 2013, 9, 803-808.	1.4	2
158	Basics of Antithrombotic Therapy for Cardiovascular Disease. Interventional Cardiology Clinics, 2013, 2, 499-513.	0.2	1
159	Cyphering the Mechanism of Late Failure of Bioresorbable Vascular Scaffolds in Percutaneous Coronary Intervention of the Left Main Coronary Artery. JACC: Cardiovascular Interventions, 2015, 8, e95-e97.	1.1	1
160	Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions. JACC: Cardiovascular Interventions, 2017, 10, 743-745.	1.1	1
161	Feasibility and Outcomes of Repeat Percutaneous Edge-to-Edge Mitral Valve Repair Procedures in Patients at High Risk for Surgery. JACC: Cardiovascular Interventions, 2018, 11, 818-820.	1.1	1
162	Early and Mid-Term Outcomes of Transcatheter Aortic Valve Replacement Using the New Generation Self-Expanding Corevalve Evolut R Device. Structural Heart, 2018, 2, 229-234.	0.2	1

#	ARTICLE	IF	CITATIONS
163	Tug of War Between Dual and Triple Antithrombotic Therapy in Atrial Fibrillation/PCI Patients With CKD. JACC: Cardiovascular Interventions, 2019, 12, 1562-1565.	1.1	1
164	EDITORIAL: 'Coapting' Clinical Evidence on Mortality Impact of MitraClip Implantation in Patients with Functional Mitral Regurgitation. Cardiovascular Revascularization Medicine, 2020, 21, 61-62.	0.3	1
165	Timing of cardioversion in atrial fibrillation: the sooner the better?. European Heart Journal Supplements, 2020, 22, L41-L43.	0.0	1
166	Exploring reasons for different bioresorbable scaffolds outcomes in women versus men: The research must go on. International Journal of Cardiology, 2020, 310, 34-36.	0.8	1
167	Managing Patients With Intermediate In-Stent Restenotic Lesions. Circulation: Cardiovascular Interventions, 2008, 1, 90-92.	1.4	0
168	Response to Letter Regarding Article, "Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease". Circulation: Cardiovascular Interventions, 2011, 4, .	1.4	0
169	Combination Antithrombotic Management of STEMI with Pharmacoinvasive Strategy, Primary PCI, or Rescue PCI. Interventional Cardiology Clinics, 2013, 2, 573-583.	0.2	0
170	Authors' Reply. Journal of the American Society of Echocardiography, 2013, 26, 219-220.	1.2	0
171	TCT-280 Drug-Coated Balloon Versus Drug-Eluting Stent For In-Stent Restenosis: A Meta-Analysis Of Randomized Controlled Trials. Journal of the American College of Cardiology, 2014, 64, B81.	1.2	0
172	One-Year Coverage by Optical Coherence Tomography of a Bioresorbable Scaffold Neocarina: Is It Safe to Discontinue Dual-Antiplatelet Therapy?. Canadian Journal of Cardiology, 2015, 31, 1205.e5-1205.e6.	0.8	0
173	Transfemoral transcatheter aortic-valve replacement should be preferred over surgery in most intermediate-risk patients. Evidence-Based Medicine, 2016, 21, 173-173.	0.6	0
174	Is the Metallic Stent a Safe Treatment for Bioresorbable Scaffold Failure?. JACC: Cardiovascular Interventions, 2016, 9, 976-977.	1.1	0
175	Update on clinical evidence (Part II): A summary of the main post market studies. Catheterization and Cardiovascular Interventions, 2016, 88, 31-37.	0.7	0
176	Retrograde Approach for Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	0
177	Interventional Treatment of Acute Coronary Syndrome (ACS): Non-ST Elevation ACS (NSTEMI-ACS). , 2017, , 51-59.		0
178	TAVI Postprocedural Management. , 2018, , 483-499.		0
179	The sunset of triple antithrombotic therapy for atrial fibrillation patients. European Heart Journal Supplements, 2019, 21, B36-B37.	0.0	0
180	Calcification and Coronary Interventions. , 2022, , 119-138.		0

#	ARTICLE	IF	CITATIONS
181	Impact of direct oral anticoagulants on evolution of post-thrombotic syndrome. <i>Thrombosis Research</i> , 2021, 207, 10-15.	0.8	0
182	Late Self-Apposition With One-Year Persisting Uncoverage of Malapposed Bioresorbable Polymeric Struts. <i>Canadian Journal of Cardiology</i> , 2017, 33, 951.e5-951.e6.	0.8	0
183	Appraisal of key trials in aortic and mitral fields. <i>EuroIntervention</i> , 2018, 14, AB19-AB32.	1.4	0
184	De-escalation of oral P2Y ₁₂ inhibitors guided by platelet function testing in ACS patients undergoing PCI: impact of diabetes mellitus. <i>EuroIntervention</i> , 2019, 15, e486-e489.	1.4	0